Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization

Modulation of the QT interval duration in hypertension with antihypertensive treatment

(2015) Jan Klimas et al.   HYPERTENSION RESEARCH

Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

(2014) Kazuomi Kario et al.   HYPERTENSION

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice

(2012) Geoffrey K. Isbister et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Graphical representation of QT rate correction formulae: an aid facilitating the use of a given formula and providing a visual comparison of the impact of different formulae

(2012) Derek J. Rowlands   JOURNAL OF ELECTROCARDIOLOGY

Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk

(2011) András Varró et al.   BRITISH JOURNAL OF PHARMACOLOGY

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor

(2008) Y H Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY